Corcept Therapeutics (CORT) Stock Price, News & Analysis

Company Overview

Corcept Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapies that modulate the effects of cortisol, a hormone implicated in a range of serious medical conditions. Founded in 1998 and headquartered in Menlo Park, California, the company emerged from research into cortisol receptor antagonists. Corcept’s strategy centers on advancing novel small-molecule drugs that address disorders driven by excessive cortisol activity, with a strong emphasis on regulatory approval and patient access.

The company’s lead product, Korlym (mifepristone), is approved for the treatment of hyperglycemia secondary to Cushing’s syndrome in adults who have type 2 diabetes or glucose intolerance and are not candidates for surgery. Korlym represents the first and only cortisol receptor antagonist indicated for this rare endocrine disorder. Corcept has built a dedicated commercial infrastructure in the United States and has expanded access programs to support patients and physicians in managing the complexities of Cushing’s syndrome.

Beyond Korlym, Corcept maintains an active pipeline of next-generation compounds designed to target a variety of cortisol-related and other serious diseases. These programs include selective glucocorticoid receptor antagonists under clinical investigation for applications in oncology, metabolic disorders and psychiatric conditions. The company collaborates with academic institutions and research organizations to advance translational studies and optimize dosing strategies for its investigational therapies.

Under the leadership of CEO Kathleen M. Healey and a team of experienced industry professionals, Corcept Therapeutics is committed to improving the lives of patients with life-altering diseases. The company leverages a patient-centric model that integrates regulatory expertise, scientific innovation and robust commercial capabilities. Corcept serves healthcare providers across North America and Europe, upholding a mission to deliver safe and effective treatments for conditions driven by cortisol dysregulation.

Key Stats

• Today's Range: $71.45 to $72.72
• 50-Day Range: $69.01 to $78.69
• 52-Week Range: $29.42 to $117.33
• Volume: 675,773 shs
• Average Volume: 1.18 million shs
• Market Capitalization: $7.70 billion
• P/E Ratio: 62.63
• Dividend Yield: N/A
• Price Target: $138.25
• Consensus Rating: Buy

Corcept Therapeutics Stock Analysis - MarketRank™

Corcept Therapeutics scored higher than 95% of companies evaluated by MarketBeat, and ranked 178th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Corcept Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Corcept Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 36.03%

Earnings Growth

Earnings for Corcept Therapeutics are expected to grow by 36.03% in the coming year, from $1.36 to $1.85 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Corcept Therapeutics is 62.63, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.53.

Price to Earnings Ratio vs. Sector

The P/E ratio of Corcept Therapeutics is 62.63, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.40.

Price to Book Value per Share Ratio

Corcept Therapeutics has a P/B Ratio of 11.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.49% of the float of Corcept Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Corcept Therapeutics has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Corcept Therapeutics has recently increased by 0.08%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Corcept Therapeutics does not currently pay a dividend.

Dividend Growth

Corcept Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.07

Percentage of Shares Shorted

13.49% of the float of Corcept Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Corcept Therapeutics has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Corcept Therapeutics has recently increased by 0.08%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.91

News Sentiment

Corcept Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Corcept Therapeutics this week, compared to 10 articles on an average week.

Search Interest

Only 7 people have searched for CORT on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

MarketBeat Follows

5 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,014,551.00 in company stock.

Percentage Held by Insiders

20.80% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

93.61% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CORT Stock Analysis - Frequently Asked Questions

How have CORT shares performed this year?

Corcept Therapeutics' stock was trading at $50.39 at the start of the year. Since then, CORT shares have increased by 44.2% and is now trading at $72.65.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) issued its earnings results on Monday, May, 5th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.17. Corcept Therapeutics's revenue was up 7.1% on a year-over-year basis.
Read the conference call transcript.

How do I buy shares of Corcept Therapeutics?

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Corcept Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Intel (INTC) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 7/03/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CORT
• CIK: 1088856
• Web: www.corcept.com
• Phone: (650) 327-3270
• Fax: 650-327-3218
• Employees: 300
• Year Founded: 1998

Price Target and Rating

• Average Stock Price Target: $138.25
• High Stock Price Target: $145.00
• Low Stock Price Target: $131.00
• Potential Upside/Downside: +90.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.16
• Trailing P/E Ratio: 62.63
• Forward P/E Ratio: 53.42
• P/E Growth: N/A
• Net Income: $141.21 million
• Net Margins: 19.33%
• Pretax Margin: 19.86%
• Return on Equity: 20.40%
• Return on Assets: 16.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.07
• Quick Ratio: 2.96

Sales & Book Value

• Annual Sales: $675.04 million
• Price / Sales: 11.41
• Cash Flow: $1.26 per share
• Price / Cash Flow: 57.44
• Book Value: $6.49 per share
• Price / Book: 11.19

Miscellaneous

• Outstanding Shares: 106,040,000
• Free Float: 83,988,000
• Market Cap: $7.70 billion
• Optionable: Optionable
• Beta: 0.15